Hypofractionated SBRT For Prostate Cancer

Prostate Cancer Clinical Trial

Official title: Prospective Evaluation Of Hypofractionated Stereotactic Body Radiotherapy For Low And Intermediate Risk Prostate Cancer

Status Completed

Clinical Trial Summary

The purpose of this study is to determine, in both low-risk and intermediate-risk cohorts, the rates of acute and late grade 3 or higher gastrointestinal and genitourinary toxicity observed during a 24 month follow up and to estimate the rate of biochemical Disease-Free Survival, Phoenix and American Society for Therapeutic Radiology and Oncology definitions, at 2 years following hypofractionated stereotactic body radiation therapy for low and intermediate risk prostate cancer.

Clinical Trial Description

Radiosurgery should be ideal for treating prostate cancer because:

• targeting accuracy for static targets is excellent, with an error of about 1mm,

• it can adjust for intra-fractional organ motion, reducing the volume of the target PTV and therefore the dose to surrounding organs,

• by using over one-hundred non-conplanar beams, the dose gradient between the prostate and surrounding tissues may be superior to that achieved with conventional linear accelerators,

• the radiobiology of prostate cancer may favor large dose per fractions. ;

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

• NCT number: NCT00977860
• Study type: Interventional
• Source: University of Pittsburgh
• Status: Completed
• Phase: N/A
• Start date: October 7, 2010
• Completion date: July 8, 2022